Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on September 12, 2006, reporting events that occurred on September 7, 2006. The filing addresses changes to the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Resignation: Wayne T. Hockmeyer, Ph.D., resigned from the Board of Directors on September 7, 2006.
- Appointment: H. Thomas Watkins was appointed to the Board as a Class I Director to fill the vacancy, with a term expiring at the 2007 annual meeting.
- Committee Assignments: Mr. Watkins was assigned to the Compensation Committee and the Nominating/Corporate Governance Committee, replacing Dr. Hockmeyer.
- Compensation: On September 8, 2006, Mr. Watkins was granted an option to purchase 35,000 shares of common stock at an exercise price of $9.40 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding business outlook, guidance, or specific risks. The stock option granted to Mr. Watkins includes a change of control provision, stating the option will accelerate and become immediately exercisable in such an event.
Key Facts for Investor Verification
- Verify the effective date of Dr. Hockmeyer's resignation and the specific reasons, if disclosed in the referenced press release (Exhibit 99.1).
- Confirm the vesting schedule details for Mr. Watkins' 35,000 share option grant.
- Review the qualifications and background of the new director, H. Thomas Watkins.
- Check subsequent filings for any further changes to the Board composition or committee structures.